Outcome Capital’s Post

Paroxysmal Nocturnal Hemoglobinuria is a rare acquired disorder of the pluripotent hematopoietic stem cell. As per DelveInsight Business Research LLP, in the United States, there are ~6,120 diagnosed prevalent cases. The only disease-modifying therapeutic strategies for PNH are complement inhibition therapies. Alexion Pharmaceuticals, Inc./AstraZeneca’s SOLIRIS (eculizumab) was the first complement inhibitor approved in 2007 for PNH. Major players such as Kira (KP104), Ionis Pharmaceuticals, Inc./Roche (RG6299), Alnylam Pharmaceuticals (cemdisiran), Omeros Corporation (OMS906) and others are advancing their therapies through early and late-stage development Crovalimab works by binding to C5, blocking the last step of the complement cascade, and is also recycled within the bloodstream, enabling rapid and sustained complement inhibition. Crovalimab’s recycling properties also enable low dose subcutaneous (SC) administration every four weeks. In addition, crovalimab binds to a different C5 binding site from current treatments, which has the potential to provide a treatment option for people with specific C5 gene mutations who do not respond to current therapies. Get detailed insights with DelveInsight Business Research LLP’s European Hematology Association (EHA) 2024 coverage @ https://lnkd.in/gJSfpia3 #PNH #ParoxysmalNocturnalHemoglobinuria #RareDisease #ComplementInhibition #HematopoieticStemCell #Alexion #AstraZeneca #SOLIRIS #Eculizumab #KiraPharmaceuticals #KP104 #IonisPharmaceuticals #Roche #RG6299 #Alnylam #Cemdisiran #Omeros #OMS906 #Crovalimab #BiotechNews #MedicalResearch #PharmaInnovation #RareDiseaseTreatment #ComplementTherapies #ClinicalTrials #FDAApproval #HealthcareAdvancements #SubcutaneousAdministration #C5Inhibition #GeneTherapy #DelveInsight #HealthStatistics #PatientCare

Have you ever wondered how your unique genetic makeup influences your response to medications? Join this insightful webinar on Pharmacogenomics—an field that explores the interaction between genetics and drug response. Pharmacogenomics holds the key to personalized medicine, revolutionizing how we prescribe and tailor treatments to individual patients. By understanding genetic variations, healthcare providers can predict how individuals will respond to medications, leading to safer and more effective therapies. You don't want to miss this webinar. #Pharmacogenomics #NextBio #DNAtesting #PersonalizedMedicine #HealthcareInnovation #Workshop #Genetics #DrugResponse #LearningOpportunity

💭 Despite new technologies emerging and existing techniques being refined, there is a critical need for biophysicists focusing on early-stage drug discovery to come together, share innovative ideas, and harness transferrable lessons to inform efficient drug discovery. The 𝗕𝗶𝗼𝗽𝗵𝘆𝘀𝗶𝗰𝘀 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝘂𝗺𝗺𝗶𝘁 provides a forum for exactly that, have you secured your pass yet? ⏳ This week only you can 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 $𝟴𝟱𝟬 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 – and that doesn’t include the discounts for bringing a colleague! But hurry, this discount expires Friday, February 9! With representatives from across the industry having confirmed their participation, this is you and your teams exclusive opportunity to immerse yourself in critical discussions on innovative applications of biophysical techniques to unlock maximum insights into molecular and target interactions. Secure your pass here: https://ter.li/m1dpy4 👩🏫 Want to share your own work? Included in your ticket is the opportunity to demonstrate your own innovations at our dedicated poster session, find out more here: https://ter.li/biophysics #biophysics #drugdiscovery #drugdesign #drugdevelopment #biophysicists

Our colleagues will be presenting at the upcoming FBLD Conference 2024 between the 22nd-25th September in Boston.  https://lnkd.in/gnvHkNyw If you are attending the conference, check out the exciting oral presentations below. Astex Presentations: 1. David Rees (Opening Keynote) - 25 Years of Thinking Small 2. Puja Pathuri - Fragment-Based Discovery of Allosteric Modulators of β-Glucocerebrosidase 3. Paul Mortenson - Marrying Structures with Computation for Augmented Fragment-Based Drug Discovery 4. Andrew Woodhead - Biological Validation of a Novel eIF4E Binding Site Identified by Fragment Screening Using Mutational Analysis and Targeted Protein Degradation #Fragments #DrugDiscovery 

📢 Upcoming Webinar Alert: Standardizing Pharmacogenomics Laboratory Processes and Reporting🔬🖥️ Join us for a critical panel discussion on the future of precision medicine and pharmacogenomics (PGx). With precision medicine at the forefront of healthcare, the need for standardized clinical laboratory processes and reporting in PGx has never been more pressing. Presented by GenomeWeb and Agena, Panel Talk: Standardizing Pharmacogenomics Laboratory Processes and Reporting will be led by past AMP president and renowned PGx thought leader Dr. Vicky Pratt, YouScript founder Kristine Ashcraft, and Glenn Sawyer, Associate Director of Clinical Genetics for Agena Bioscience, on Tuesday, March 19th, 2024, from 1:00-2:00 PM ET. Whether you're a healthcare professional, researcher, or someone interested in the latest developments in precision medicine, this webinar will provide valuable perspectives on standardizing PGx laboratory processes and reporting. Reserve your spot now! https://lnkd.in/exqTccY2 Sign up even if you can't attend, and we'll send you the recording and key takeaways! Share this post with your colleagues and friends who may be interested in learning more about PGx testing. #PrecisionMedicine #Webinar #PGx #HealthcareInnovation #Pharmacogenetics #Panel #Pharmacogenomics #PGxExperts

Today's the day! 🎉 Join us for the 2nd Biophysical Summit - Exploring New Paths in Biophysical Characterization, hosted by KBI Biopharma and Applied Photophysics. See you there! #BiophysicalSummit #KBI #AppliedPhotophysics

In two weeks begins #ICMS® 𝗶𝗻 𝗖𝗮𝗺𝗯𝗿𝗶𝗱𝗴𝗲, 𝗨𝗞 from 𝟭𝟵-𝟮𝟬 𝗝𝘂𝗻𝗲, 𝟮𝟬𝟮𝟰. Have you checked what is on the agenda? Annette Dolphin, professor at UCL explains her motivation for joining us: “𝘚𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘤𝘢𝘯 𝘢𝘳𝘪𝘴𝘦 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘶𝘯𝘭𝘪𝘬𝘦𝘭𝘺 𝘰𝘧 𝘥𝘪𝘳𝘦𝘤𝘵𝘪𝘰𝘯𝘴, 𝘢𝘯𝘥 𝘴𝘩𝘰𝘶𝘭𝘥 𝘯𝘦𝘷𝘦𝘳 𝘣𝘦 𝘥𝘪𝘴𝘮𝘪𝘴𝘴𝘦𝘥.  𝘈𝘴 𝘐 𝘸𝘪𝘭𝘭 𝘥𝘪𝘴𝘤𝘶𝘴𝘴, 𝘮𝘺 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘢𝘳𝘺 𝘮𝘪𝘤𝘳𝘰𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘴𝘵 𝘐𝘨𝘰𝘳 𝘡𝘩𝘶𝘭𝘪𝘯 𝘱𝘳𝘰𝘷𝘦𝘥 𝘴𝘶𝘳𝘱𝘳𝘪𝘴𝘪𝘯𝘨𝘭𝘺 𝘧𝘳𝘶𝘪𝘵𝘧𝘶𝘭, 𝘧𝘰𝘳 𝘣𝘰𝘵𝘩 𝘰𝘧 𝘶𝘴.” Check out the full program and sign-up for the waiting list here: https://lnkd.in/dTcNxnWv Unfortunately, we are fully booked for this event. If you didn't get a spot, don't worry. The talks will be recorded and made available on our website after the symposium. The Sophion Bioscience 𝗜𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗠𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 will feature keynote speakers, poster presentations, and give you excellent networking opportunities. We are gathering researchers, scientists, and industry professionals to share ideas, stimulate discussions, foster collaborations, share the latest advancements in the modulation of ion channels, and explore new frontiers in the field. #ICMS #Qube384 #QPatch #QPatchCompact #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

📢 Excited to share our new iteration of the PhoreMost pipeline, advancing our phenotypic screening applications - GlueSEEKER! Watch this space... or should I say, you'll be "GLUEd to your (our) Screens?!?!". No, I most definitely shouldn't, that's a terrible play on words. The technology is cool though! Check it out below! #MolecularGlues #TPD

Why should you attend ICMS® in Boston? Here’s a word of advice from Principal Scientist Edward Humphries, a frequent ICMS attendee: “𝗔𝘀 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆, 𝗜𝗖𝗠𝗦 𝗶𝘀 𝗮 𝗺𝘂𝘀𝘁-𝗮𝘁𝘁𝗲𝗻𝗱 𝗲𝘃𝗲𝗻𝘁 𝗳𝗼𝗿 𝗺𝗲 𝗲𝘃𝗲𝗿𝘆 𝘆𝗲𝗮𝗿. 𝗧𝗵𝗲 𝗹𝗲𝗰𝘁𝘂𝗿𝗲𝘀 𝗰𝗼𝘃𝗲𝗿 𝗮 𝘄𝗶𝗱𝗲 𝗿𝗮𝗻𝗴𝗲 𝗼𝗳 𝘁𝗼𝗽𝗶𝗰𝘀, 𝗳𝗿𝗼𝗺 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 (𝘄𝗲 𝗲𝘃𝗲𝗻 𝘀𝗮𝘄 𝘀𝗼𝗺𝗲 𝘀𝗶𝗻𝗴𝗹𝗲-𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴𝘀 𝗹𝗮𝘀𝘁 𝘆𝗲𝗮𝗿) 𝘁𝗼 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗳𝗿𝗼𝗺 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗹𝗶𝗸𝗲 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗮𝗻𝗱 𝗔𝘂𝘁𝗶𝗳𝗼𝗻𝘆 𝗶𝗻 𝗿𝗲𝗰𝗲𝗻𝘁 𝘆𝗲𝗮𝗿𝘀. 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗮𝘁 Maxion Therapeutics, 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗮𝗻𝗱 𝗚𝗣𝗖𝗥-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, 𝗜𝗖𝗠𝗦 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝘀 𝗮 𝗴𝗿𝗲𝗮𝘁 𝘄𝗮𝘆 𝘁𝗼 𝗺𝗲𝗲𝘁 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰𝘀 𝗶𝗻 𝗮 𝗿𝗲𝗹𝗮𝘅𝗲𝗱, 𝗶𝗻𝘁𝗶𝗺𝗮𝘁𝗲 𝘀𝗲𝘁𝘁𝗶𝗻𝗴 𝘄𝗵𝗲𝗿𝗲 𝗶𝗱𝗲𝗮𝘀 𝗳𝗹𝗼𝘄 𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗮𝗿𝗲 𝗰𝗿𝗲𝗮𝘁𝗲𝗱.” If you haven't registered for the event, you can sign up now here: https://ow.ly/wP6h50SC63a Our ICMS® brings together researchers, scientists, and industry professionals from around the world to exchange ideas, share the latest advancements, and explore new frontiers in ion channel modulation. The event will feature keynote speakers, poster presentations, and excellent networking opportunities. We look forward to spending two days together filled with inspiring talks and discussions. Don't miss out – sign up now while seats are still available. The symposium fills up quickly. #ICMS #Qube384 #QPatch #QPatchCompact #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion